Kowa Company Limited

D. Western Therapeutics Institute, Inc.

Masami Shiratsuchi

Seiichi Sato

Kiyoshi Kawamura

Hiroyuki Ishiwata

Takeo Deushi

Yasumi Uchida

Toshihiro Akashi

Toshiaki Oda

Hiromichi Shigyo

Masahiko Nagakura

Yoshio Takahashi

Hisashi Kunieda

Soichi Oda

Mototsugu Kabeya

Makoto Suda

Hiroshi Nakao

Takao Nagoya

Takeshi Ohshima

Manabu Shibasaki

Yukio Hattori

Masahiro Tamura

Yoshinori Kyotani

Mitsuteru Hirata

Nobuo Aoki

Masahito Nakayama

Shigeru Kimura

Hiroshi Ishihama

Noboru Shimizu

Naotoshi Sawada

Hiroyuki Sonoki

Yukihiro Sato

Kimiyuki Shibuya

Kazuhiro Onogi

Isamu Watanabe

Toshiyuki Edano

Katsumi Kawamine

Hisakatsu Ito

Yukihiro Okuno

Souhei Tanabe

Tetsuya Ishikawa

Hiroyoshi Hidaka

Kazuhiro Kamiya

Hisakatsu Itoh

Katsuhiro Yamamoto

Naoki Machida

Naoki Machida, Deceased

By Takayasu Miwa, Heir

The present invention is directed to (S)-(&#x2212;)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1,4-homopiperazine hydrochloride dihydrate, to a method producing the dihydrate, and to a drug composition containing the dihydrate. The compound of the present invention has less hygroscopicity as compared with (S)-(&#x2212;)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1,4-homopiperazine hydrochloride anhydrous crystals and thus, exhibits excellent chemical stability.

(S)-(-)-1-(4-fluoroisoquinolin-5-Yl)Sulfonyl-2-methyl-1,4-homopiperazine hydrochloride dihydrate

Diamide compound and medicine containing the same

Anilide compounds and pharmaceutical compositions comprising them

Diamide compounds and compositions containing the same

Diamide compound and drugs containing the same

Pyrimidine derivatives

The present invention relates to compounds represented by the following general formula (1):

Anilide compounds, including use thereof in ACAT inhibitition

Pyrimidine derivatives as endothelin antagonists

Azoxy compound

A compound expressed by the formula: ##STR1## in which R.sub.11, R.sub.21 and R.sub.31 are identical with or different from each other and each denotes a hydrogen atom, a halogen atom, an alkyl group, an alkenyl group, a haloalkyl group, an alkoxy group, an alkylthio group, an aryl or an aralkyl group which aromatic ring is optionally substituted appropriately by one to three substituents or a heterocyclic group optionally substituted appropriately by one to three substituents, or R.sub.11 and R.sub.21 may together form an alkylene group, Y denotes O or NOH, with a proviso that where R.sub.21 (or R.sub.11) and R.sub.31 denote a hydrogen atom at the same time, R.sub.11 (or R.sub.21) cannot represent an n-butyl group. This compound is useful as an antifungal agent.

Azoxy compounds

Thrombin-binding substances are obtained by fractionating human urine by ion-exchange chromatography, affinity chromatography using a thrombin-bound carrier, immune adsorption column chromatography, gel filtration, and/or molecular-weight fractionation. One of the substances has a molecular weight of 46,500.+-.6,000 in reduced condition and 39,000.+-.10,000 in unreduced condition by SDS PAGE and an isoelectric point at pH 5.0-5.3, while the other has a molecular weight of 40,000.+-.8,000 in reduced condition and 31,000.+-.10,000 in unreduced condition by SDS PAGE and an isoelectric point at pH 4.9-5.7. They have strong affinity to thrombin. They are capable of promoting the thrombin catalyzed activation of protein C and prolong clotting time. They are stable to denaturing agents (urea and sodium dodecylsulfate).

Thrombin-binding substance and process for its preparation

Novel thrombin-binding substances (A) and (B) are disclosed. The thrombin-binding substances have the following characteristics:

Thrombin-binding protein substance and process for preparing the same

Growing community of inventors

Musashimurayama, Japan

Masami Shiratsuchi